Literature DB >> 26901012

Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study.

Stephanie M McCann1, Yulei Jiang1, Xiaobing Fan1, Jianing Wang1, Tatjana Antic2, Fred Prior3, David VanderWeele4, Aytekin Oto1.   

Abstract

OBJECTIVE: The objective of our study was to investigate associations between quantitative image features of multiparametric MRI of the prostate and PTEN expression of peripheral zone prostate cancer.
MATERIALS AND METHODS: A total of 45 peripheral zone cancer foci from 30 patients who had undergone multiparametric prostate MRI before prostatectomy were identified by a genitourinary pathologist and a radiologist who reviewed histologic findings and MR images. Histologic sections of cancer foci underwent immunohistochemical analysis and were scored according to the percentage of tumor-positive cells expressing PTEN as negative (0-20%), mixed (20-80%), or positive (80-100%). Average and 10th percentile apparent diffusion coefficient (ADC) values, skewness of T2-weighted signal intensity histogram, and quantitative perfusion parameters (i.e., forward volume transfer constant [K(trans)], extravascular extracellular volume fraction [ve], and reverse reflux rate constant between the extracellular space and plasma [k(ep)]) from the Tofts model were calculated for each cancer focus. Associations between the quantitative image features and PTEN expression were analyzed with the Spearman rank correlation coefficient (r).
RESULTS: Analysis of the 45 cancer foci revealed that 21 (47%) were PTEN-positive, 12 (27%) were PTEN-negative, and 12 (27%) were mixed. There was a weak but significant negative correlation between Gleason score and PTEN expression (r = -0.30, p = 0.04) and between k(ep) and PTEN expression (r = -0.35, p = 0.02). There was no significant correlation between other multiparametric MRI features and PTEN expression.
CONCLUSION: This preliminary study of radiogenomics of peripheral zone prostate cancer revealed weak-but significant-associations between the quantitative dynamic contrast-enhanced MRI feature k(ep) and Gleason score with PTEN expression. These findings warrant further investigation and validation with the aim of using multiparametric MRI to improve risk assessment of patients with prostate cancer.

Entities:  

Keywords:  Gleason score; dynamic contrast-enhanced MRI; phosphatase and tensin homolog (PTEN); prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26901012     DOI: 10.2214/AJR.15.14967

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  20 in total

Review 1.  Arguments against using an abbreviated or biparametric prostate MRI protocol.

Authors:  Felipe B Franco; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2020-12

Review 2.  Background, current role, and potential applications of radiogenomics.

Authors:  Katja Pinker; Fuki Shitano; Evis Sala; Richard K Do; Robert J Young; Andreas G Wibmer; Hedvig Hricak; Elizabeth J Sutton; Elizabeth A Morris
Journal:  J Magn Reson Imaging       Date:  2017-11-02       Impact factor: 4.813

3.  Radiogenomic analysis of PTEN mutation in glioblastoma using preoperative multi-parametric magnetic resonance imaging.

Authors:  Yiming Li; Yuchao Liang; Zhiyan Sun; Kaibin Xu; Xing Fan; Shaowu Li; Zhong Zhang; Tao Jiang; Xing Liu; Yinyan Wang
Journal:  Neuroradiology       Date:  2019-06-19       Impact factor: 2.804

4.  Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma.

Authors:  Neema Jamshidi; Daniel J Margolis; Steven Raman; Jiaoti Huang; Robert E Reiter; Michael D Kuo
Journal:  Radiology       Date:  2017-04-28       Impact factor: 11.105

5.  Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients.

Authors:  Gang Wu; Weiyuan Huang; Junnv Xu; Wenzhu Li; Yu Wu; Qianyu Yang; Kun Liu; Mingyue Zhu; Priya S Balasubramanian; Mengsen Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-08-16       Impact factor: 4.553

Review 6.  Overview of radiomics in prostate imaging and future directions.

Authors:  Hwan-Ho Cho; Chan Kyo Kim; Hyunjin Park
Journal:  Br J Radiol       Date:  2021-11-29       Impact factor: 3.039

7.  Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer.

Authors:  Simpa S Salami; Jeremy B Kaplan; Srinivas Nallandhighal; Mandeep Takhar; Jeffrey J Tosoian; Matthew Lee; Junhee Yoon; Daniel H Hovelson; Komal R Plouffe; Samuel D Kaffenberger; Edward M Schaeffer; R Jeffrey Karnes; Tamara L Lotan; Todd M Morgan; Arvin K George; Jeffrey S Montgomery; Matthew S Davenport; Sungyong You; Scott A Tomlins; Nicole E Curci; Hyung L Kim; Daniel E Spratt; Aaron M Udager; Ganesh S Palapattu
Journal:  JCO Precis Oncol       Date:  2019-06-12

Review 8.  Background, applications and challenges of radiogenomics in genitourinary tumor.

Authors:  Longfei Liu; Xiaoping Yi; Can Lu; Yingxian Pang; Xiongbing Zu; Minfeng Chen; Xiao Guan
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

9.  PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.

Authors:  David J VanderWeele; Baris Turkbey; Adam G Sowalsky
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-12-12

10.  Diagnostic Value of 68Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study.

Authors:  BaoJun Wang; Jie Gao; Qing Zhang; Yao Fu; Guangxiang Liu; Jiong Shi; Danyan Li; Feng Wang; Hongqian Guo
Journal:  J Nucl Med       Date:  2019-11-22       Impact factor: 11.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.